肠道微生物群和多酚之间的复杂相互作用已成为理解和潜在利用这些生物活性化合物治疗潜力的迷人前沿。酚类化合物,以其抗氧化剂而闻名,抗炎,抗糖尿病药,和抗癌特性,在肠道环境中受到复杂的变化,多样的微生物生态系统对其代谢和生物利用度产生深远的影响。相反,多酚表现出显著的调节肠道微生物群的组成和活性的能力,培养一种超越单纯营养加工的双向关系。这种共生相互作用对人类健康具有重要意义,特别是在心脏代谢疾病如糖尿病,代谢功能障碍相关的脂肪变性肝病,和心血管疾病。通过对分子相互作用的全面探索,这篇叙述性综述阐明了肠道微生物群和多酚之间的相互动力学,揭示心脏代谢紊乱治疗干预的新途径。通过解开这两个实体之间复杂的串扰,这篇综述强调了多酚在整体健康中的多方面作用,以及肠道微生物群调节作为减轻心脏代谢疾病负担的有前景的治疗策略的关键作用.
The intricate interplay between the gut microbiota and polyphenols has emerged as a captivating frontier in understanding and potentially harnessing the therapeutic potential of these bioactive compounds. Phenolic compounds, renowned for their antioxidant, anti-inflammatory, antidiabetic, and anticancer properties, are subject to intricate transformations within the gut milieu, where the diverse microbial ecosystem exerts profound effects on their metabolism and bioavailability. Conversely, polyphenols exhibit a remarkable capacity to modulate the composition and activity of the gut microbiota, fostering a bidirectional relationship that extends beyond mere nutrient processing. This symbiotic interaction holds significant implications for human health, particularly in cardiometabolic diseases such as diabetes mellitus, metabolic-dysfunction-associated steatotic liver disease, and cardiovascular disease. Through a comprehensive exploration of molecular interactions, this narrative
review elucidates the reciprocal dynamics between the gut microbiota and polyphenols, unveiling novel avenues for therapeutic intervention in cardiometabolic disorders. By unravelling the intricate cross-talk between these two entities, this
review underscores the multifaceted roles of polyphenols in overall health and the pivotal role of gut microbiota modulation as a promising therapeutic strategy in mitigating the burden of cardiometabolic diseases.